Payment overview · 2025
General Payments
$653.59
35 reported records · 12 companies
Healthcare provider profile · identity verified
Brent A Bader, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OXFORD, OH · NPI 1437163151
Verified facts
What the public records show
CMS Open Payments records show Brent A Bader, MD received $653.59 in general payments during 2025 across 35 reported records.
Novo Nordisk Inc accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 467 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $189.87 | 29.1% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $93.37 | 14.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $79.49 | 12.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.46 | 10.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.82 | 8.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.68 | 5.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.06 | 4.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.61 | 4.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.11 | 3.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.14 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.40 | 2.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.58 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $653.59 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $154.73 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $129.36 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.52 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $50.63 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.74 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.68 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.68 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.14 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.68 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 165 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 122 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 39 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
104 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
467 | 70 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1359 | 362 |
| Amlodipine Besylate | Amlodipine Besylate | 994 | 251 |
| Levothyroxine Sodium | Levothyroxine Sodium | 756 | 180 |
| Lisinopril | Lisinopril | 538 | 145 |
| Omeprazole | Omeprazole | 504 | 139 |
| Eliquis | Apixaban | 467 | 70 |
| Metformin Hcl | Metformin Hcl | 447 | 129 |
| Losartan Potassium | Losartan Potassium | 445 | 123 |
| Potassium Chloride | Potassium Chloride | 420 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 396 | 110 |
| Furosemide | Furosemide | 389 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 330 | 93 |
| Carvedilol | Carvedilol | 308 | 85 |
| Famotidine | Famotidine | 289 | 66 |
| Simvastatin | Simvastatin | 289 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 257 | 68 |
| Alprazolam | Alprazolam | 253 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 245 | 70 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 237 | 65 |
| Glimepiride | Glimepiride | 225 | 60 |
| Donepezil Hcl | Donepezil Hcl | 222 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 41 |
| Allopurinol | Allopurinol | 175 | 49 |
| Lorazepam | Lorazepam | 172 | 40 |
| Meloxicam | Meloxicam | 169 | 50 |
| Jardiance | Empagliflozin | 165 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 46 |
| Trazodone Hcl | Trazodone Hcl | 162 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 161 | 41 |
| Prednisone | Prednisone | 159 | 72 |
| Gabapentin | Gabapentin | 158 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 153 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 151 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 57 |
| Memantine Hcl | Memantine Hcl | 140 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 137 | 39 |
| Valsartan | Valsartan | 136 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 38 |
| Ozempic | Semaglutide | 122 | 23 |
| Cephalexin | Cephalexin | 118 | 80 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 116 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 115 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 106 | 33 |
| Synthroid | Levothyroxine Sodium | 104 | 29 |
| Spironolactone | Spironolactone | 103 | 28 |
| Buspirone Hcl | Buspirone Hcl | 101 | 23 |
| Mirtazapine | Mirtazapine | 101 | 20 |
| Alendronate Sodium | Alendronate Sodium | 97 | 27 |
| Myrbetriq | Mirabegron | 96 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 96 | 26 |
| Metformin Hcl Er | Metformin Hcl | 95 | 27 |
| Warfarin Sodium | Warfarin Sodium | 92 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 24 |
| Promethazine Hcl | Promethazine Hcl | 88 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 86 | 26 |
| Celecoxib | Celecoxib | 85 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 15 |
| Montelukast Sodium | Montelukast Sodium | 77 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 26 |
| Amoxicillin | Amoxicillin | 74 | 64 |
| Ezetimibe | Ezetimibe | 74 | 24 |
| Midodrine Hcl | Midodrine Hcl | 66 | 15 |
| Torsemide | Torsemide | 66 | 16 |
| Atenolol | Atenolol | 65 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 16 |
| Tramadol Hcl | Tramadol Hcl | 63 | 17 |
| Finasteride | Finasteride | 60 | 16 |
| Methocarbamol | Methocarbamol | 60 | suppressed |
| Pregabalin | Pregabalin | 60 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 12 |
| Bupropion Xl | Bupropion Hcl | 58 | 17 |
| Trulicity | Dulaglutide | 58 | 18 |
| Xarelto | Rivaroxaban | 56 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 11 |
| Ibuprofen | Ibuprofen | 53 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 51 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 50 | 40 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 49 | suppressed |
| Nifedipine Er | Nifedipine | 48 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 14 |
| Sucralfate | Sucralfate | 47 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 37 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 16 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 39 | 12 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Nystatin | Nystatin | 39 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 39 | 39 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | 11 |
| Benazepril Hcl | Benazepril Hcl | 38 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 21 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Fluconazole | Fluconazole | 37 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 16 |
| Digoxin | Digoxin | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 25 |
| Rybelsus | Semaglutide | 35 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Naproxen | Naproxen | 33 | 11 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 18 |
| Klor-Con M20 | Potassium Chloride | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 20 |
| Methimazole | Methimazole | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Tradjenta | Linagliptin | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Diazepam | Diazepam | 22 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 18 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Droxidopa | Droxidopa | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $653.59 · 35 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPVAXIVE, GARDASIL 9, GEMTESA, INSPIRE, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error